Compare Neurocrine Biosciences Inc (NBIX) vs Wayfair Inc (W) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Wayfair Inc — how do they compare? Neurocrine Biosciences Inc trades at $141.13 (market cap $14.36B), while Wayfair Inc trades at $104.47 (market cap $14.40B). The key difference: Neurocrine Biosciences Inc and Wayfair Inc are close in size by market cap, and Wayfair Inc is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Wayfair Inc for 8 Days on average.
| NBIX | W | |
|---|---|---|
Market Cap | $14.36B | $14.40B |
Volume | 1,237,180 | 2,102,856 |
Sector | Health | Consumer Cyclical |
52-Week High | $185.50 | $119.05 |
52-Week Low | $123.10 | $57.40 |
Typical Hold Time | 23 Days | 8 Days |
Enterprise Value | $14.37B | $16.73B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a 20.91% net income margin and consistent earnings beats, including a Q2 2026 EPS of $2.85 versus $1.85 expected. Recent news highlights pipeline advancements in Prader-Willi syndrome and active participation in investor conferences. Key support is at $142, with resistance at $145.
The outlook is positive, driven by robust product growth, particularly from Ingrezza and Crenessity, and a deep pipeline. Risks include pricing pressures on Ingrezza by 2029 and execution challenges in portfolio expansion. Analyst consensus is strongly bullish with a $204.18 price target, suggesting significant upside from current levels.
Wayfair (W) trades at $104.47, down 0.93% on the day, showing mixed technical signals with a bullish moving average trend but neutral oscillators. Fundamentally, the company reported $12.46B revenue for 2025 but posted a net loss of $313M, with negative profit margins. Recent earnings show volatility, beating estimates in Q4 2025 and Q2 2026 but missing in Q1 2026. Analyst sentiment remains positive with a 54% buy rating and $114.13 consensus price target, while the company expands physically with new store openings.
The outlook for Wayfair hinges on improving profitability amid ongoing losses. Near-term catalysts include Q3 2026 earnings on November 4, 2026, where meeting the $0.785 EPS estimate could boost sentiment. Risks include high debt-to-asset ratio of 95.11% and competitive pressures in online retail. The stock offers 9.2% upside to the consensus target, but investors should monitor cash flow trends after 2026's negative net cash flow of $261M.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Wayfair Inc
Wayfair is a global leader in home goods, operating a massive digital marketplace that connects millions of consumers with thousands of suppliers. It utilizes an asset-light, inventory-light model combined with a proprietary logistics network (CastleGate) and an accelerating brick-and-mortar presence to deliver an end-to-end shopping experience for everything from decor to full home renovations.
Read more on W →
